moderna

Respiratory vaccines

Program Pack

RSV (mRNA-1345)

mRESVIA (mRNA-1345): Moderna's RSV vaccine for adults 60 and older has been approved in multiple regions

mRESVIA® (Respiratory Syncytial Virus Vaccine)

- Approved by the U.S. FDA for adults aged 60+; also approved in other international regions for adults aged 60+ including Australia, Switzerland, Taiwan and the UK
- Approved by the U.S. FDA in adults aged 18–59 at increased risk for RSV disease

RSV vaccine (mRNA-1345) encodes for a stabilized prefusion F glycoprotein



RSV is the leading cause of respiratory illness in young children and older adults are at high risk for severe RSV infections

Disease burden in pediatrics

- Hospitalization rate in children <5 years old in the U.S.: ~3:1000[1]
- Annually ~2 million medically attended RSV infections in children <5 years old in the U.S., with up to 80,000 hospitalized[2]
- Pediatric RSV results in an estimated ~$2 billion in annual medical costs in the U.S.
- Almost all children will have had an RSV infection by their second birthday[3]

Long-term RSV infection sequelae[6]

- Recurrent wheeze
- Asthma
- Impaired lung function

Disease burden in older adults

- There are up to 160,000 hospitalizations in adults 65+ due to RSV in the U.S. each year, and up to 10,000 deaths[4]
- In industrialized countries, it is estimated that there are ~1.5 million episodes of acute respiratory tract infection in older adults annually; globally, it is estimated that there are ~336,000 hospitalizations related to RSV in older adults each year[5]

Long-term RSV infection sequelae[7]

- Exacerbation of chronic obstructive pulmonary disease
- Higher 1 year mortality after severe illness

(1) Rha, Brian, et al., *Pediatrics* (2020), https://doi.org/10.1542/peds.2019-3611
(2) RSV Surveillance & Research, CDC, https://www.cdc.gov/rsv/research/index.html
(3) Respiratory Syncytial Virus Infection (RSV), CDC, https://www.cdc.gov/rsv/about/symptoms.html
(4) RSV in Older Adults and Adults with Chronic Medical Conditions, CDC, https://www.cdc.gov/rsv/high-risk/older-adults.html
(5) Shi, Ting, et al., *J Infect Dis.* (2020), https://doi.org/10.1093/infdis/jiz059.
(6) Shi, Ting et al., *J Infect Dis*. (2020), https://doi.org/10.1093/infdis/jiz311
(7) Ackerson, Bradley et al., *Clin Infect Dis.*(2019), https://doi.org/10.1093/cid/ciy991

RSV (mRNA-1345) development program in adults >50 years old

Adults
(Ages: 60+)

Phase 3
P301 Part A

- Pivotal Phase 3 efficacy and safety

Adults
(Ages: 60+)

Phase 3
P301 Part B

- 24-month revaccination

Adults
(Ages: 50+)

Phase 3
P302 Part A

- Standard dose influenza vaccine co-administration

Adults
(Ages: 50+)

Phase 3
P302 Part B

- COVID-19 vaccine co-administration

Adults
(Ages: 50+)

Phase 3
P302 Part C

- 12-month revaccination

Adults
(Ages: 65+)

Phase 3
P304

- High dose influenza vaccine co-administration

RSV (mRNA-1345) P301 Part A older adult pivotal safety and efficacy

Phase 2/3 pivotal vaccine efficacy and safety trial designed to evaluate the safety, tolerability, and efficacy of mRNA-1345 (50 µg) in adults ≥ 60 years of age

Design
Randomized 1:1, observer-blind, placebo-controlled study

Participants
~37,000 adults ≥ 60 years of age (Phase 2:~2000; Phase 3: ~35,000)

Vaccination schedule
Single dose of mRNA-1345 (50 µg) or placebo

Duration
Participants followed up for 24 months after study injection

Site locations
22 countries

Phase 2/3 pivotal efficacy
≥ 60 years of age
Total N ~ 37,000

mRNA-1345	Placebo
N~18,500	N~18,500

moderna

RSV vaccine efficacy met primary and key secondary endpoints in primary analysis

Study 301 per protocol analysis, median follow up of 3.7 months (maximum of 12.6 months) after vaccine/placebo

	Cases, n (%)		
	mRNA-1345 (N = 17,572)	**Placebo** (N = 17,516)	**Vaccine Efficacy (%) Based on Hazard Ratios[1]**
RSV LRTD ≥ 2 symptoms	9 (0.05%)	55 (0.31%)	**83.7%** (66.0%, 92.2%)
RSV LRTD ≥ 3 symptoms	3 (0.02%)	17 (0.10%)	**82.4%** (34.8%, 95.3%)
RSV ARD	26 (0.15%)	82 (0.47%)	**68.4%** (50.9%, 79.7%)



The results of the primary efficacy and safety analysis of this Phase 2/3 efficacy study were published in the NEJM[1]

1.https://www.nejm.org/doi/full/10.1056/NEJMoa2307079?query=featured_home

RSV neutralizing antibody responses are similar across age groups, including ≥ 80 years old

Study 301 – RSV neutralizing antibody (IU/mL)



- Baseline titers similar across age groups
- Day 29 titers and fold rise are similar across age groups

Primary and additional analyses confirm durable protection through full 2022-2023 RSV season for mRNA-1345



RSV efficacy study conducted across 2021 – 2022 and 2022 – 2023 seasons

>50% of participants enrolled in US

Primary Analysis:
Met success criteria[2]

Additional Analysis: 94% of participants followed for ≥6 months

*Median RSV hospitalization rate for 2016 – 2019. Data only collected from October to April each year.

1. CDC. Respiratory Syncytial Virus Hospitalization Surveillance Network (RSV-NET). https://data.cdc.gov/Public-Health-Surveillance/Weekly-Rates-of-Laboratory-Confirmed-RSV-Hospitali/29hc-w46k/data_preview. 2. Wilson E, et al. NEJM. 2023;389:2233-2244.

Additional analysis: efficacy of mRNA-1345 against RSV LRTD among adults ≥ 60 Years

Unblinded analysis, median follow-up of 8.6 months (maximum of 17.7 months) after vaccine/placebo

Cases, n (%)

	RSV Vaccine (mRNA-1345) (N = 18,112)	Placebo (N = 18,045)	Vaccine Efficacy (%) Based on Hazard Ratios (95% CI)
RSV LRTD ≥ 2 symptoms	47 (0.26%)	127 (0.70%)	**63.3%** (48.7%, 73.7%)
RSV LRTD ≥ 3 symptoms	19 (0.10%)	51 (0.28%)	**63.0%** (37.3%, 78.2%)
RSV ARD	86 (0.47%)	185 (1.03%)	**53.9%** (40.5%, 64.3%)
RSV-LRTD Associated Shortness of Breath[1]	11/18,101 (0.06%)	43/18,002 (0.24%)	**74.6%** (50.7%, 86.9%)

RSV-LRTD ≥ 2 symptoms



- Vaccine protection continues over a longer period (median 8.6 months) through high-transmission 2022/2023 RSV season
- Lower bound of the confidence interval continued to exceed 20%

1. Shortness of breath was a post hoc analysis

mRNA-1345 reactogenicity

Study 301 - Solicited Safety Set

Solicited Local Reactions within 7 Days After RSV Vaccine vs Placebo



RSV vaccine, n=18174; placebo, n=18102
For placebo, grade 2 erythema and grade 2 and grade 3 swelling were < 1%
No grade 4 local adverse reactions

Solicited Systemic Reactions within 7 Days After RSV Vaccine vs Placebo



RSV vaccine, n=18174; placebo, n=18102
Grade 4 fever was reported (mRNA-1345 [n=29] and placebo [n=35]); no other categories reported any grade 4 reactions

Grade 1 Grade 2 Grade 3

mRNA-1345 Phase 3 in older adults – summary of primary analysis

Efficacy

- 83.7% and 82.4% vaccine efficacy against RSV-LRTD with ≥2 and > 3 signs/symptoms, respectively
- Secondary analysis was performed according to the presence/absence of medical comorbidities for RSV-LRTD with ≥2 symptoms
  - VE for RSV-LRTD with no comorbidity was 81.6%
  - VE for RSV-LRTD with ≥ 1 comorbidity was 88.4%

Safety

- Pain was the most frequently reported local solicited symptom
- Headache, fatigue, myalgia and arthralgia were the most frequently reported systemic solicited symptoms
- Most solicited adverse reactions were grade 1 or grade 2
- No cases of GBS or ADEM have been reported in mRNA-1345 Phase 3 study
- No safety concerns identified

mRNA-1345 Phase 3 P303 Part A: High-risk adults 18 to <60 years

Study designed to test the immunogenicity and safety of mRNA-1345 in high-risk adults 18 to < 60 years of age

Design
Randomized, double-blind study

Participants
1,003 high risk adults aged 18 to <60 years

Vaccination schedule
Single dose of mRNA-1345

Duration
24 months

Site locations
United States, UK, Puerto Rico, and Canada



Primary immunogenicity endpoint
GMT of 50 µg mRNA-1345 in high-risk adults (18 to < 60 years) compared with 50 µg mRNA-1345 in pivotal P301 efficacy study (≤ 60 years)

High risk is defined as Coronary artery disease and/or congestive heart failure, Chronic lung disease, or Stable type 1 or type 2 diabetes mellitus controlled with at least 1 medication started 90 days or more prior to Day 1

mRNA-1345 met all primary immunogenicity endpoints in high-risk adults 18 to < 60 years

High risk adults 18 to < 60 years compared to pivotal P301 efficacy study (≥ 60 years)



GMR non-inferiority criteria were met
(LB of the 2-sided 95% CI of GMR > 0.667)

mRNA-1345 50 µg dose was well-tolerated in high-risk adults 18 to < 60 years





P303: High risk 18 to < 60 years
P301: Pivotal efficacy study; > 60 years

*1 grade 4 fever was verified as data error

mRNA-1345 Phase 3 18–59-year-olds at high-risk Part A safety

mRNA-1345 50 µg dose was well tolerated in 18–59-year-olds at high risk of RSV-LRTD

The tolerability of 50 µg of mRESVIA in 18-59 year old high risk adults was comparable to that observed among older adults in the pivotal efficacy study P301

Up to 28 days after vaccination, there were no related unsolicited adverse events resulting in study discontinuation, deaths, AESI, or related SAEs

No events of anaphylaxis related to vaccination, thrombocytopenia, Guillain Barre Syndrome, or acute disseminated encephalomyelitis (ADEM) were reported after vaccination

No new safety concerns to alter the existing mRESVIA safety assessment were identified

mRNA-1345 high-risk adults 18 to < 60 Summary

Immunogenicity

- mRNA-1345 met all primary immunogenicity endpoints in high-risk adults 18 to < 60 years
- Demonstration of non-inferiority compared to immune responses in the pivotal efficacy trial (P301; > 60 years), thus inferring effectiveness in this high-risk younger adult population

Reactogenicity / Safety

- mRNA-1345 50 µg dose was well-tolerated with no new safety concerns identified in high-risk adults 18 to < 60 years

Next steps

- Awaiting FDA regulatory action with PDUFA data of June 12, 2025

Medical conference presentations

- Slides 19-31 were taken from February 2023 presentation at the 7th ReSViNET Conference (RSVVW 2023)
- Slides 32-45 were taken from April 2023 presentation at European Congress of Clinical Microbiology & Infectious Diseases (ECCMID)

Safety and Efficacy of mRNA-1345, an mRNA-based Vaccine Against Respiratory Syncytial Virus, in Adults 60 Years and Older

Eleanor Wilson, Jaya Goswami, Sonia K. Stoszek, Runa Mithani, Shraddha Mehta, Archana Kapoor, Wenmei Huang, Lan Lan, Laila El Asmar, Catherine A. Panozzo, Parinaz Ghaswalla, Allison August, Christine A. Shaw, Jacqueline Miller, Grace L. Chen

February 23, 2023
Presented at the 7th ReSViNET Conference (RSVVW 2023)
Lisbon, Portugal

Disclosures, Acknowledgments, and Abstract Plain Language Summary

EW, JG, SKS, RM, SM, AK, WH, LL, LEA, CAP, PG, AA, CAS, JM, and GLC are employees of Moderna, Inc., and hold stock/stock options in the company

Medical writing and editorial assistance were provided by Jared Mackenzie, PhD, of MEDiSTRAVA in accordance with Good Publication Practice (GPP3) guidelines, funded by Moderna, Inc., and under the direction of the authors

This study was funded by Moderna, Inc.

Abstract plain language summary

- Please scan the QR code for an infographic plain language summary of the submitted abstract
- Copies of this summary obtained through the QR code are for personal use only and may not be reproduced without written permission of the authors

mRNA-1345, an mRNA-based RSV Vaccine, Encodes for a Stabilized Prefusion F Glycoprotein

mRNA-1345 is an mRNA-based RSV vaccine candidate consisting of a single mRNA sequence encoding the membrane-anchored RSV F glycoprotein stabilized in the prefusion conformation

Prefusion F elicits superior neutralizing antibody responses compared to post-fusion F[1,2]

F protein antibodies cross-react between RSV-A and RSV-B[3]

Phase 1 data show that mRNA-1345 is well tolerated and boosts antibody levels through 6 months[4]



F, fusion; LNP, lipid nanoparticle; mRNA, messenger ribonucleic acid.

1. Crank MC, et al. *Science*. 2019;365:505-509. 2. McKekkan JS, et al. *Science*. 2013;342(6158):592-598. 3. Aranda SS and Polack FP. *Front Immunol*. 2019;10:1006. 4. Chen GL, et al. *Open Forum Infect Dis*. 2022;9(suppl 2):ofac492.312.

mRNA-1345 Phase 2/3 Clinical Trial

In this ongoing phase 2/3, randomized, double-blind, placebo-controlled, case-driven study in adults aged ≥60 years (NCT05127434)[1], 35,541 participants from 22 countries were randomized 1:1 to receive 1 dose of mRNA-1345 50 µg or placebo

- Healthy participants were included, as well as medically stable participants with ≥1 chronic medical diagnoses

Study Schedule – Phase 3



Trial Sites



Primary Efficacy Endpoints

Vaccine efficacy of mRNA-1345 to **prevent a first episode of RSV lower respiratory tract disease (LRTD) with ≥2 or ≥3 symptoms** between 14 days to 12 months following injection

mRNA-1345 Phase 2/3 Clinical Trial: Efficacy Endpoint Definition

Two Primary Endpoint Definitions for RSV Lower Respiratory Tract Disease (LRTD)

RSV LRTD with 2 or more lower respiratory symptoms

- RT-PCR-confirmed RSV *PLUS*
- Radiologic evidence of pneumonia

OR

- New or worsening of 2 or more of the following symptoms for ≥24 hours:

RSV LRTD with 3 or more lower respiratory symptoms

- RT-PCR-confirmed RSV PLUS
- Radiologic evidence of pneumonia

OR

- New or worsening of 3 or more of the following symptoms for ≥24 hours:

LRTD Symptoms

- Shortness of breath
- Cough and/or fever
- Wheezing/rales/rhonchi
- Sputum production
- Tachypnea
- Hypoxemia
- Pleuritic chest pain

Demographics and Baseline Characteristics

	mRNA-1345 (N=17,793)	Placebo (N=17,748)
Age at Enrollment (Years), Mean (SD)	68.1 (6.19)	68.1 (6.20)
Age Group, n (%)[a]		
60 to 69 Years	11,315 (63.6)	11,270 (63.5)
70 to 79 Years	5493 (30.9)	5478 (30.9)
≥80 Years	985 (5.5)	1000 (5.6)
Sex, n (%)		
Male	9100 (51.1)	9004 (50.7)
Female	8693 (48.9)	8744 (49.3)
Comorbidities of Interest, n (%)[b]		
0	12,535 (70.4)	12,593 (71.0)
≥1	5258 (29.6)	5155 (29.0)

	mRNA-1345 (N=17,793)	Placebo (N=17,748)
Race Groups, n (%)		
White	11,285 (63.4)	11,254 (63.4)
Black	2210 (12.4)	2173 (12.2)
Asian	1541 (8.7)	1535 (8.6)
Other[c]	2688 (15.1)	2680 (15.1)
Unknown/Not Reported	69 (0.4)	106 (0.6)
Ethnicity, n (%)		
Hispanic or Latino	6112 (34.4)	6162 (34.7)
Not Hispanic or Latino	11,495 (64.6)	11,377 (64.1)
Unknown	27 (0.2)	22 (0.1)
Not Reported	159 (0.9)	187 (1.1)

Demographics and baseline characteristics were well matched across groups

Note: Data are from the Randomization Set analysis population.
CHF, congestive heart failure; COPD, chronic obstructive pulmonary disease; LRTD, lower respiratory tract disease; mRNA, messenger ribonucleic acid; SD, standard deviation.
[a]Derived from age and risk collected on electronic case report forms. [b]Comorbidities of interest include COPD, asthma, chronic respiratory disease, diabetes, CHF, advanced liver disease, or advanced renal disease.
[c]Other race includes American Indian or Alaska Native, Native Hawaiian or other Pacific Islander, Other, or Multiple.

moderna

Overview of Solicited Adverse Reactions

	mRNA-1345	Placebo
Solicited local adverse reactions within 7 days		
Solicited local adverse reactions within 7 days, n/N (%)	10,367/17,662 (58.7%)	2845/17,593 (16.2%)
Grade 3 or greater cases, n/N (%)	558/17,662 (3.2%)	305/17,593 (1.7%)
Solicited systemic adverse reactions within 7 days		
Solicited systemic adverse reactions within 7 days, n/N (%)	8432/17,662 (47.7%)	5798/17,597 (32.9%)
Grade 3 or greater cases, n/N (%)	710/17,662 (4.0%)	508/17,597 (2.9%)

- To date, most solicited adverse reactions were mild to moderate
- The most commonly reported solicited adverse reactions in the mRNA-1345 group were injection site pain, fatigue, headache, myalgia, and arthralgia

Percentage of Participants With Solicited Local Adverse Reactions Within 7 Days



Pain at the injection site (mostly grade 1) was the most frequently reported local adverse reaction

Note: Data are from the Solicited Safety Set analysis population.
Summary of participants with solicited adverse reactions within 7 days after injection by grade; placebo (n = 17,598); mRNA-1345 50 µg (n = 17,665).
Note: *For placebo, grade 2 for erythema and grade 2 and grade 3 or above for swelling are <0.1%.
mRNA, messenger ribonucleic acid.

Percentage of Participants With Solicited Systemic Adverse Reactions Within 7 Days



Arthralgia, fatigue, headache, and myalgia were the most frequently reported systemic adverse reactions

Note: Data are from the Solicited Safety Set analysis population.
Summary of participants with solicited adverse reactions within 7 days after injection by grade; placebo (n = 17,598); mRNA-1345 50 µg (n = 17,665).
Note: *For placebo, grade 2 for erythema and grade 2 and grade 3 or above for swelling are <0.1%.
mRNA, messenger ribonucleic acid.

Efficacy of mRNA-1345 Against RSV LRTD

	mRNA-1345 (N=17,572)	Placebo (N=17,516)
RSV LRTD with ≥2 symptoms		
Cases, n/N (%)[a,b]	9/17,572 (0.05%)	55/17,516 (0.31%)
VE (%) based on hazard ratios (alpha adjusted 95.88% CI)[c]	**83.7% (66.0%, 92.2%)**	
RSV LRTD with ≥3 symptoms		
Cases, n/N (%)[a,b]	3/17,572 (0.02%)	17/17,516 (0.10%)
VE (%) based on hazard ratios (alpha adjusted 96.36% CI)[c]	**82.4% (34.8%, 95.3%)**	

Note: Data are from the Per-Protocol Efficacy Set analysis population, 14 days to 12 months post-injection.
CI, confidence interval; LRTD, lower respiratory tract disease; mRNA, messenger ribonucleic acid; RT-PCR, reverse transcription polymerase chain reaction; VE, vaccine efficacy.
[a]Protocol-defined RSV-LRTD with ≥2 and ≥3 symptoms is based on eligible symptoms onset within a timeframe of +/- 14 days from positive RSV RT-PCR collection date.
[b]The time to first occurrence of protocol-defined RSV-LRTD with ≥2 and ≥3 symptoms will be calculated as date of case — date of randomization + 1.
[c]VE is defined as 100% x (1 — hazard ratio [mRNA-1345 vs. placebo]). The CI for VE is based on a stratified Cox proportional hazard model with Efron's method of tie handling and with the treatment group as a fixed effect, adjusting for stratification factors at randomization.

Efficacy of mRNA-1345 Against RSV LRTD Across Age Groups



In adults ≥80 years, no cases of RSV LRTD with ≥2 or ≥3 symptoms were observed (mRNA-1345, n/N=0/964; PBO, n/N=0/982)

Note: Data are from the Per-Protocol Efficacy Set analysis population, 14 days to 12 months post-injection.
CI, confidence interval; LRTD, lower respiratory tract disease; mRNA, messenger ribonucleic acid; NE, not evaluated; PBO, placebo; RSV, respiratory syncytial virus; RT-PCR, reverse transcription polymerase chain reaction; VE, vaccine efficacy
[a]Protocol-defined RSV-LRTD with ≥2 and ≥3 symptoms is based on eligible symptoms onset within a timeframe of +/- 14 days from positive RSV RT-PCR collection date.
[b]The time to first occurrence of protocol-defined RSV-LRTD with ≥2 and ≥3 symptoms will be calculated as date of case — date of randomization + 1.
[c]VE is defined as 100% x (1 — hazard ratio [mRNA-1345 vs. placebo]). The CI for VE is based on a stratified Cox proportional hazard model with Efron's method of tie handling and with the treatment group as a fixed effect, adjusting for stratification factors at randomization.

Efficacy of mRNA-1345 Against RSV LRTD in Participants With Pre-existing Comorbidities



Note: Data are from the Per-Protocol Efficacy Set analysis population, 14 days to 12 months post-injection.
CHF, congestive heart failure; CI, confidence interval; COPD, chronic obstructive pulmonary disease; LRTD, lower respiratory tract disease; mRNA, messenger ribonucleic acid; RSV, respiratory syncytial virus; RT-PCR, reverse transcription polymerase chain reaction; VE, vaccine efficacy.
[1]Comorbidities of interest include COPD, asthma, chronic respiratory disease, diabetes, CHF, advanced liver disease, or advanced renal disease. [2]Protocol-defined RSV-LRTD with ≥2 and ≥3 symptoms is based on eligible symptoms onset within a timeframe of +/- 14 days from positive RSV RT-PCR collection date. [3]The time to first occurrence of protocol-defined RSV-LRTD with ≥2 or ≥3 symptoms will be calculated as date of case — date of randomization + 1. [4]VE is defined as 100% x (1 — hazard ratio [mRNA-1345 vs. placebo]). The CI for VE is based on a stratified Cox proportional hazard model with Efron's method of tie handling and with the treatment group as a fixed effect, adjusting for stratification factors at randomization.

Conclusions

mRNA-1345 was well tolerated and had an acceptable safety profile; solicited adverse reactions were mostly grade 1 or grade 2 in severity

A single dose of mRNA-1345 50 µg is efficacious in preventing RSV LRTD with ≥2 or ≥3 symptoms in adults aged ≥60 years within 14 days to 12 months following injection

Vaccine efficacy was consistently high across all age groups and in participants with pre-existing comorbidities

The phase 3 clinical trial of mRNA-1345 in adults aged ≥60 years is ongoing, with additional supportive analyses planned through 24 months

Safety and efficacy of a respiratory syncytial virus vaccine (mRNA-1345), against a spectrum of symptomatic disease in adults aged ≥60 years

Jaya Goswami, Eleanor Wilson, Sonia K. Stoszek, Runa Mithani, Shraddha Mehta, Archana Kapoor, Wenmei Huang, Lan Lan, Jiejun Du, Laila El Asmar, Catherine A. Panozzo, Parinaz Ghaswalla, Beverly M. Francis, Alana K. Simorellis, Christine A. Shaw, Jacqueline M. Miller, Grace L. Chen

16 April 2023
33rd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID); 15-18 April 2023
Copenhagen, Denmark

Disclosures, Acknowledgments, and Abstract Plain Language Summary

JG, EW, SKS, RM, SM, AK, WH, LL, JD, LE, CAP, PG, BMF, AKS, CAS, JMM, and GLC are employees of Moderna, Inc., and hold stock/stock options in the company

Editorial assistance was provided by MEDiSTRAVA in accordance with Good Publication Practice (GPP3) guidelines, funded by Moderna, Inc., and under the direction of the authors

This study was funded by Moderna, Inc.

Abstract plain language summary

- Please scan the QR code for an infographic plain language summary of the submitted abstract
- Copies of this summary obtained through the QR code are for personal use only and may not be reproduced without written permission of the authors

Overview of Respiratory Syncytial Virus (RSV)

- **RSV is a common and highly infectious respiratory pathogen** that co-circulates as two different subtypes, RSV-A and RSV-B[1]
- **The burden of RSV in older adults is underestimated** due to inconsistent and insensitive diagnostic testing, limited data from low- and middle-income regions and lack of standardized case definition[2,3,4]
- Across high-income countries in 2019, **RSV caused an estimated ~5.2 million cases, 470,000 hospitalizations, and 33,000 in-hospital deaths in adults aged ≥60 years**[2]
- After adjusting for under detection, a recent study estimated that **the United States sees 1.36 million RSV-associated outpatient visits in adults aged ≥65 years, and 1.08 million RSV-associated outpatient visits in adults aged 50-64 each year**[3]

Potential impact of RSV infection sequelae[3]

Severe acute respiratory infection and lower respiratory tract infections

Exacerbation of asthma and chronic obstructive pulmonary disease

Higher 1 year mortality after severe illness with RSV than influenza

Griffiths C et al. 2017. *Clin Microbiol Rev*; 30(1):277-319. 2. Savic, M et al. 2022. *Influenza Other Respi Viruses;*17(1):e13031. 3. McLaughlin JM et al. *Open Forum Infec Dis*. 2022; 9(7):ofac300. 4. Nguyen-Van-Tam, JS et al. 2022. *Eur Respir Rev;* 31: 220105

mRNA-1345, an mRNA-based RSV Vaccine, Encodes for a Stabilized Prefusion F Glycoprotein

mRNA-1345 is an mRNA-based RSV vaccine candidate consisting of a single mRNA sequence encoding the membrane-anchored RSV F glycoprotein stabilized in the prefusion conformation

Prefusion F elicits superior neutralizing antibody responses compared to post-fusion F[1,2]

F protein antibodies cross-react between RSV-A and RSV-B[3]

Phase 1 data show that mRNA-1345 is well tolerated and boosts antibody levels through 6 months[4]



F, fusion; LNP, lipid nanoparticle; mRNA, messenger ribonucleic acid; RSV, respiratory syncytial virus.

1. Crank MC, et al. *Science*. 2019;365:505-509. 2. McKekkan JS, et al. *Science*. 2013;342(6158):592-598. 3. Aranda SS, Polack FP. *Front Immunol*. 2019;10:1006. 4. Chen GL, et al. *Open Forum Infect Dis*. 2022;9(suppl 2):ofac492.312.

mRNA-1345 Phase 2/3 Clinical Trial

In this ongoing phase 2/3, randomized, double-blind, placebo-controlled, case-driven study in adults aged ≥60 years (NCT05127434),[1] 35,541 participants from 22 countries were randomized 1:1 to receive 1 dose of mRNA-1345 50 µg or placebo[2]

- Healthy participants were included, as well as medically stable participants with ≥1 comorbidities of interest

Study Schedule – Phase 3



Trial Sites

Key Efficacy Endpoints

- Vaccine efficacy of mRNA-1345 to **prevent a first episode of RSV lower respiratory tract disease (LRTD) with ≥2 or ≥3 symptoms** between 14 days to 12 months following injection
- Vaccine efficacy of mRNA 1345 to **prevent a first episode of RSV acute respiratory disease (ARD)** within the period of 14 days post-injection up to 12 months post-injection

Note: Study schedule data are from the Randomization Set analysis population. Data cut-off for analysis was 30 November 2022.
Solicited local and systemic adverse reactions were collected up to 7 days post-injection; unsolicited adverse events were collected up to 28 days post-injection; medically attended adverse events, adverse events of special interest, serious adverse events, and adverse events leading to withdrawal are collected up to 24 months post-injection.
ARD, acute respiratory disease; D, day; LRTD, lower respiratory tract disease; M, month; mRNA, messenger ribonucleic acid; RSV, respiratory syncytial virus.

1. ClinicalTrials.gov. NCT05127434. https://clinicaltrials.gov/ct2/show/NCT05127434.
2. Enrolment numbers as of 31 October 2022

Definitions of ARD and LRTD

ConquerRSV

Phase 2/3 Safety and Efficacy Study of mRNA-1345

RT-PCR Confirmed RSV +

RSV Acute Respiratory Disease (ARD)

New or Worsening of ≥1 of Following Symptoms for ≥24 Hours

Sinus pain	Hoarseness	Stuffy Nose	Tachypnea	Shortness of breath	Sputum production	Wheezing and/or rales and/or rhonchi
Sore Throat	Runny Nose	Chills	Hypoxemia	Fever	Pleuritic chest pain	
				Cough		

LRTD cases are a subset of the ARD cases

RSV Lower Respiratory Tract Disease (LRTD)

New or Worsening of ≥2 or ≥3 of Following Symptoms for ≥24 Hours

Tachypnea	Shortness of breath	Sputum production	Wheezing and/or Rales and/or rhonchi
Hypoxemia	Fever and/ or Cough	Pleuritic chest pain	

In case of inability to fully assess other clinical parameters, radiologic evidence of pneumonia with RT-PCR-confirmed RSV infection also can be used to confirm RSV-ARD or RSV-LRTD

moderna

Demographics and Baseline Characteristics

	mRNA-1345 (N=17,793)	Placebo (N=17,748)
Age at Enrollment (Years), Mean (SD)	68.1 (6.19)	68.1 (6.20)
Age Group, n (%)[a]		
60 to 69 Years	11,315 (63.6)	11,270 (63.5)
70 to 79 Years	5493 (30.9)	5478 (30.9)
≥80 Years	985 (5.5)	1000 (5.6)
Sex, n (%)		
Male	9100 (51.1)	9004 (50.7)
Female	8693 (48.9)	8744 (49.3)
Comorbidities of Interest, n (%)[b]		
0	12,535 (70.4)	12,593 (71.0)
≥1	5258 (29.6)	5155 (29.0)

	mRNA-1345 (N=17,793)	Placebo (N=17,748)
Race Groups, n (%)		
White	11,285 (63.4)	11,254 (63.4)
Black	2210 (12.4)	2173 (12.2)
Asian	1541 (8.7)	1535 (8.6)
Other[c]	2688 (15.1)	2680 (15.1)
Unknown/Not Reported	69 (0.4)	106 (0.6)
Ethnicity, n (%)		
Hispanic or Latino	6112 (34.4)	6162 (34.7)
Not Hispanic or Latino	11,495 (64.6)	11,377 (64.1)
Unknown	27 (0.2)	22 (0.1)
Not Reported	159 (0.9)	187 (1.1)

Demographics and baseline characteristics were well matched across groups

Note: Data are from the Randomization Set analysis population.
CHF, congestive heart failure; COPD, chronic obstructive pulmonary disease; LRTD, lower respiratory tract disease; mRNA, messenger ribonucleic acid; SD, standard deviation.
[a]Derived from age and risk collected on electronic case report forms. [b]Comorbidities of interest include COPD, asthma, chronic respiratory disease, diabetes, CHF, advanced liver disease, or advanced renal disease.
[c]Other race includes American Indian or Alaska Native, Native Hawaiian or other Pacific Islander, Other, or Multiple.

moderna

Percentage of Participants With Solicited Local Adverse Reactions Within 7 Days



Pain at the injection site (mostly grade 1) was the most frequently reported local adverse reaction

Note: Data are from the Solicited Safety Set analysis population.
Summary of participants with solicited adverse reactions within 7 days after injection by grade; placebo (n = 17,598); mRNA-1345 50 µg (n = 17,665).
Note: *For placebo, grade 2 for erythema and grade 2 and grade 3 or above for swelling are <0.1%.
mRNA, messenger ribonucleic acid.

Percentage of Participants With Solicited Systemic Adverse Reactions Within 7 Days



Arthralgia, fatigue, headache, and myalgia were the most frequently reported systemic adverse reactions

Note: Data are from the Solicited Safety Set analysis population.
Summary of participants with solicited adverse reactions within 7 days after injection by grade; placebo (n = 17,598); mRNA-1345 50 µg (n = 17,665).
Note: *For placebo, grade 2 for erythema and grade 2 and grade 3 or above for swelling are <0.1%.
mRNA, messenger ribonucleic acid.

Unsolicited Treatment-Emergent Adverse Events Within 28 Days After Injection, Regardless of Relationship to Vaccine/Placebo

	mRNA-1345 50 µg (N=17734)		Placebo (N=17679)	
	n	%	n	%
All	3624	**20.4%**	3331	**18.8%**
Serious	102	**0.6%**	93	**0.5%**
Fatal	2	**<0.1%**	4	**<0.1%**
Medically Attended	1842	**10.4%**	1739	**9.8%**
Leading to Study Discontinuation	2	**<0.1%**	9	**<0.1%**
Severe/≥ Grade 3	124	**0.7%**	119	**0.7%**
Non-Serious[a]	3522	**19.9%**	3238	**18.3%**
Any Adverse Event of Special Interest (AESI)	3	**<0.1%**	8	**<0.1%**

No significant imbalances in any of these events between vaccine & placebo recipients

Note: Data are from the Safety Set analysis population as of 30 November 2022.
A TEAE is defined as any event not present before exposure to study vaccination or any event already present that worsens in intensity or frequency after exposure. Severe TEAEs include both unsolicited severe TEAEs and ≥ grade 3 solicited ARs that meet SAE criteria or last beyond 7 days after injection.
Medically Attended TEAEs include ED/urgent care, outpatient physician visits and per-protocol illness visits.
[a]Participants who did not report any serious TEAE are included in the summary of "non-serious."
AR, adverse reaction; ED, emergency department; mRNA, messenger RNA; SAE, serious adverse event; TEAE, treatment-emergent adverse event.

moderna

Vaccine Efficacy Against RSV-LRTD With ≥2 and ≥3 Symptoms and RSV-ARD

	Numbers of Events		
	mRNA-1345 N=17,572	**Placebo** N=17,516	**Vaccine Efficacy** (CI*)
RSV-LRTD ≥2 Symptoms	**9**	**55**	**83.7%** (66.0, 92.2)
RSV-LRTD ≥3 Symptoms	**3**	**17**	**82.4%** (34.8, 95.3)
RSV-ARD	**26**	**82**	**68.4%** (50.9, 79.7)



Data are from the Per-Protocol Efficacy Set analysis population.
VE is defined as 100% x (1 — hazard ratio (mRNA-1345 vs placebo).
*CI for VE is based on a stratified Cox proportional hazard model, with Efron's method of tie handling and with treatment group as a fixed effect, adjusting for stratification factors at randomization.
Red dotted reference line indicates lower bound used to declare success for VE.
Adjusted CIs: Overall RSV-LRTD with ≥2 symptoms, 95.88%; Overall RSV-LRTD with ≥3 symptoms, 96.36%; Overall RSV-ARD, 95% CI.
ARD, acute respiratory disease; CI, confidence interval; LRTD, lower respiratory tract disease; mRNA, messenger ribonucleic acid; RSV, respiratory syncytial virus; VE, vaccine efficacy.

Vaccine Efficacy Against RSV-A and RSV-B by Endpoint Among Adults ≥60 Years

		Numbers of Events		
		mRNA-1345 N = 17,572	Placebo N = 17,516	Vaccine Efficacy (CI*)
RSV-LRTD ≥ 2 Symptoms	Overall	9	55	**83.7%** (66.0, 92.2)
	RSV-A	3	36	**91.7%** (73.0, 97.4)
	RSV-B	6	19	**68.5%** (21.1, 87.4)
RSV-LRTD ≥ 3 Symptoms	Overall	3	17	**82.4%** (34.8, 95.3)
	RSV-A	1	10	**90.0%** (22.0, 98.7)
	RSV-B	2	7	**71.5%** (-37.0, 94.1)
RSV-ARD	Overall	26	82	**68.4%** (50.9, 79.7)
	RSV-A	11	51	**78.5%** (58.8, 88.8)
	RSV-B	15	31	**51.7%** (10.6, 73.9)



Data are from the Per-Protocol Efficacy Set analysis population.
VE is defined as 100% x (1 — hazard ratio (mRNA-1345 vs placebo).
*CI for VE is based on a stratified Cox proportional hazard model with Efron's method of tie handling and with treatment group as a fixed effect, adjusting for stratification factors at randomization
Red dotted reference line indicates lower bound used to declare success for VE.
Adjusted CIs: Overall RSV-LRTD with ≥2 symptoms, 95.88%; Overall RSV-LRTD with ≥3 symptoms, 96.36%; RSV-A and B subtype, 95% CI.
CI, confidence interval; LRTD, lower respiratory tract disease; mRNA, messenger ribonucleic acid; RSV, respiratory syncytial virus; VE, vaccine efficacy.

moderna

Summary of Signs/Symptom Assessment for First Occurrence of RSV-ARD Cases With ≥1 Signs/Symptom(s) Between 14 Days and 12 Months Following Injection



Data are from the Per-Protocol Efficacy Set analysis population.
ARD, acute respiratory disease; mRNA, messenger ribonucleic acid; RSV, respiratory syncytial virus.

Conclusions

The global trial population was racially diverse, with a sizeable enrollment of participants outside of North America/Europe as well as those with comorbidities that put them at risk for RSV

A single 50-µg dose of mRNA-1345 showed consistently high efficacy across the clinical spectrum of RSV disease in adults aged ≥60 years, including LRTD with ≥2 or ≥3 symptoms, ARD with ≥1 symptom, and across RSV-A and RSV-B subtypes within 14 days to 12 months following injection

The phase 3 clinical trial of mRNA-1345 in adults aged ≥60 years is ongoing, with additional supportive analyses planned through 24 months

mRNA-1345 was well-tolerated and had an acceptable safety profile in adults aged ≥60 years

These preliminary data suggest that the symptom profile, including symptoms indicative of severity, occur at a lower frequency in vaccinated than in placebo groups

RSV vaccine (mRNA-1345) Phase 1 in pediatric and adult populations

Overview
Evaluating the tolerability and reactogenicity of mRNA-1345 in younger adults, older adults, children, older adults of Japanese descent and women of child-bearing potential

Outcome measures
Safety and immunogenicity

- Neutralizing antibody titers against RSV

Phase 1 Trial Design

Cohorts 1-4 ✓	**Younger Adults** (18-49 years)
Cohorts 5-6 ✓	**RSV Seropositive Children** (12-59 months)
Cohorts 7-11 ✓	**Older Adults** (65-79 years)
Cohorts 12-14 ✓	**Women of Child-Bearing Potential** (18-40 years)
Cohorts 15 ✓	**Japanese Descent Older Adults** (≥ 60 Years)

In older adults, mRNA-1345 boosts RSV neutralizing antibodies



- All participants had nAb against RSV at baseline (BL) before study injections, suggesting prior exposure to RSV
- mRNA-1345 boosted RSV-A and RSV-B nAb GMTs
- GMFR over BL at 1 month were 9.8–16.9 and 5.3–12.3 for RSV-A and RSV-B, respectively
- Minimal dose-response was observed for nAb GMTs

Interim data, Per-Protocol analysis set.
Participants were randomised to receive one dose of mRNA-1345 (12.5, 25, 50, 100, or 200 µg; n=47–48 each) or placebo (n=59).
1/2 of the participants dosed with mRNA will get a booster at the same dose-level as the initial dose, at 12 months

In older adults, mRNA-1345 is well-tolerated at all dose levels



SAR, solicited adverse reactions; AEs, adverse events; SAE, severe adverse events; AESI, adverse events of special interest
Placebo (n = 55); mRNA-1345 12.5 µg (n = 46); mRNA-1345 15 µg (n = 44); mRNA-1345 50 µg (n = 47); mRNA-1345 100 µg (n = 47); mRNA-1345 200 µg (n = 47)

- Local SARs were reported in 50.0%–78.7% and 12.7% of mRNA-1345 and placebo recipients, respectively
  - Pain at the injection site (mostly grade 1) was the most frequently reported
- Systemic SARs were reported in 50.0%-78.7% and 45.5% of mRNA-1345 and placebo recipients, respectively
  - Headache, fatigue, arthralgia, and myalgia were the most frequently reported
- Treatment related unsolicited AEs were reported by 6.7% (16/239) of mRNA-1345 and 10.2% (6/59) of placebo recipients
- Unsolicited severe AEs were reported by 7 (2.9%) of the RNA-1345 recipients with none reported in the placebo group
- No related SAE or AESI were reported

Medical and scientific presentations

ECSMID 2025 (revaccination at 24 months in ages 60+)

https://s29.q4cdn.com/435878511/files/doc_presentations/2025/Apr/15/RSV-LB-Poster-P301-Part-B-24M-Revax.pdf

ECSMID 2025 (six-month immunogenicity age 60+)

https://s29.q4cdn.com/435878511/files/doc_presentations/2025/Apr/14/RSV-e-Poster-P301-Part-A-6M-Immunogenicity-Analysis-93.pdf

ECSMID 2025 (Burden of risk-factor conditions for ages 18-59)

https://s29.q4cdn.com/435878511/files/doc_presentations/2025/Apr/14/RSV-Poster-Claims-Descriptive-Analysis-18-59-years-indication-poster.pdf

ISIRV 2025 (12-month revaccination data)

https://s29.q4cdn.com/435878511/files/doc_presentations/2025/Mar/13/ISIRV-2025_12-m-revaccination-final-Read-Only.pdf

ISIRV 2025 (adults at increased risk ages 18-59)

https://s29.q4cdn.com/435878511/files/doc_presentations/2025/Mar/11/ISIRV-2025_RSV-P303-Part-A-6M-Safety-Poster_Final.pdf

RSVVW 2023 (Phase 3 data ages 60+)

https://s29.q4cdn.com/435878511/files/doc_presentations/2023/03/rsvvw-p301-ia-oral-presentation_final.pdf

Forward-looking statements

This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including regarding: the vaccine efficacy of mRNA-1345; the potential for mRNA-1345 to reduce disease burden from RSV; the safety and tolerability profile of mRNA-1345; potential market size; and ongoing clinical trials. In some cases, forward-looking statements can be identified by terminology such as “may,” “should,” “expects,” “intends,” “plans,” “aims,” “anticipates,” “believes,” “estimates,” “predicts,” “potential,” “continue,” or the negative of these terms or other comparable terminology, although not all forward -looking statements contain these words. The forward-looking statements in this presentation are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties and other factors, many of which are beyond Moderna’s control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These risks, uncertainties and other factors include those described in Moderna’s most recent Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (SEC) and in subsequent filings made by Moderna with SEC, which are available on the SEC's website at www.sec.gov. Except as required by law, Moderna disclaims any intention or responsibility for updating or revising any forward-looking statements in this presentation in the event of new information, future developments or otherwise. These forward-looking statements are based on Moderna’s current expectations and speak only as of the date referenced on the first page.